Document Detail

Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults.
MedLine Citation:
PMID:  16344836     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Assess the bioavailability of mixed amphetamine salts extended-release (MAS XR) 30-mg capsules and the dose proportionality of pharmacokinetic measures for MAS XR 20, 40, and 60 mg. METHODS: Study A, an open-label single-period study, and Study B, a randomized, open-label, three-way crossover study, were conducted in healthy adults in a clinical research unit. In Study A, 20 subjects received a single MAS XR 30-mg capsule by mouth daily for 7 days. In Study B, 12 subjects received single oral doses of MAS XR 20, 40, and 60 mg separated by 7-14-day washout periods. FINDINGS: Plasma dextroamphetamine (d-amphetamine) and levoamphetamine (l-amphetamine) concentrations were measured using a validated LC-MS/MS method. In Study A, a 3:1 ratio of d-amphetamine to l-amphetamine was observed for AUC0-inf and Cmax. Tmax was 4.2 and 4.3 hours for d-amphetamine to l-amphetamine, respectively. In Study B, for d- and l-amphetamine, statistically significant differences were observed for AUC0-t, AUC0-inf, and Cmax between all doses; there was a linear relationship between pharmacokinetic variables and dose and Tmax was similar for each isomer (range: 4.5-5.3 hours) with all given MAS XR doses. CONCLUSION: The extent of exposure as assessed by mean AUC0-24 and Cmax reflected the 3:1 ratio of d-amphetamine to l-amphetamine in MAS XR 30-mg capsules. The pharmacokinetic profiles of MAS XR 20, 40, and 60 mg are dose proportional for the isomers.
Susan B Clausen; Stephanie C Read; Simon J Tulloch
Related Documents :
2834536 - Acute effects of delta-9-tetrahydrocannabinol in rhesus monkeys as measured by performa...
9329056 - Behavioral effects of trichloroethylene and tetrachloroethylene in mice.
9259016 - No major differences in locomotor responses to dexamphetamine in high and low responder...
8888996 - Lsd produces place preference and flavor avoidance but does not produce flavor aversion...
1756516 - Inhibitory effects of ixora javanica extract on skin chemical carcinogenesis in mice an...
7628206 - A comparative study on the return to ovulation following chronic use of once-a-month in...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  CNS spectrums     Volume:  10     ISSN:  1092-8529     ISO Abbreviation:  CNS Spectr     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-13     Completed Date:  2006-03-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9702877     Medline TA:  CNS Spectr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  6-15     Citation Subset:  IM    
Shire Pharmaceutical Inc., Wayne, PA 19087, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Amphetamines / administration & dosage,  adverse effects,  pharmacokinetics*
Attention Deficit Disorder with Hyperactivity / blood*,  drug therapy
Biological Availability
Cross-Over Studies
Delayed-Action Preparations
Dextroamphetamine / blood
Dose-Response Relationship, Drug
Drug Administration Schedule
Metabolic Clearance Rate
Middle Aged
Reg. No./Substance:
0/Amphetamines; 0/Delayed-Action Preparations; 51-64-9/Dextroamphetamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Magnetic resonance imaging changes in a patient with migraine attack and transient global amnesia af...
Next Document:  Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD.